Jun 25, 2026 07:02AM
Jun 25, 2026 07:00AM
Apr 30, 2026 07:00AM
Apr 13, 2026 07:01AM
Apr 13, 2026 07:00AM
Feb 26, 2026 07:00AM
Jan 13, 2026 07:01AM Kymera Therapeutics outlines 2026 clinical trial plans
Jan 13, 2026 07:00AM
Dec 11, 2025 07:02AM
Dec 11, 2025 07:00AM
Nov 16, 2025 03:00PM
Oct 31, 2024 07:30AM
Oct 9, 2024 07:01AM
Oct 9, 2024 07:00AM Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader
Jun 20, 2024 08:45AM
Jan 17, 2024 08:00AM
Nov 2, 2023 09:00AM
Nov 2, 2023 07:00AM
Oct 27, 2023 07:00AM
Sep 18, 2023 07:01AM
Sep 18, 2023 07:00AM Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapse
Aug 3, 2023 07:00AM
Jun 22, 2023 08:30AM
May 4, 2023 07:00AM
Feb 23, 2023 07:00AM
Feb 23, 2023 07:00AM
Jan 10, 2023 07:07AM
Jan 10, 2023 07:00AM Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company
Jan 10, 2023 07:00AM
Dec 14, 2022 07:24AM
Dec 14, 2022 07:00AM
Dec 14, 2022 07:00AM
Nov 3, 2022 07:05AM
Nov 3, 2022 07:05AM
Sep 15, 2022 07:30AM Kymera Therapeutics (KYMR) Granted FDA Orphan Drug Designation for KT-333
Sep 15, 2022 07:30AM
Aug 11, 2022 10:01AM
Aug 9, 2022 07:00AM
Jun 15, 2022 07:01AM
Jun 15, 2022 07:00AM
Jun 1, 2022 08:43AM
Jun 1, 2022 08:42AM Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Peripheral T-Cell Lymphoma
May 3, 2022 07:00AM
May 3, 2022 07:00AM
Feb 24, 2022 07:00AM
Feb 24, 2022 07:00AM
Nov 30, 2021 08:02AM
Nov 30, 2021 08:00AM
Nov 30, 2021 08:00AM Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413
Nov 10, 2021 07:00AM

325,552 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All